Canada· CA-DIN-02272210
SOMAVERT
A pegvisomant product containing pegvisomant, registered in Canada by PFIZER CANADA ULC. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Pegvisomant is registered in 14 of 19 countries.
Countries holding a registration under ATC H01AX01 (pegvisomant), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Pegvisomant · ATC H01AX01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of pegvisomant costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pegvisomant · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$81.23
- ES Spain$77.80
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- PEGVISOMANT
- Manufacturer
- PFIZER CANADA ULC
- Country
- Canada (CA)
- ATC code
- H01AX01
- ATC class
- Pegvisomant
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
87 interactions on record for pegvisomant.
Graded by severity as the source publishes them — 87 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pegvisomant · interactions on record
87 records
- 87 moderate
Most severe, free to view
- OpiumA07DA02moderate
- LiraglutidA08AX02moderate
- SemaglutidA08AX03moderate
- Insulin (human)A10AB01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pegvisomant in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSOMAVERTPfizer Europe MA EEIG, Bruxelles
- SpainSOMAVERT 10 MG POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEPfizer Europe Ma Eeig
- BelgiumSomavert 10 mgPfizer Europe MA
- NetherlandsSomavert 10 mg, poeder en oplosmiddel voor oplossing voor injectiePfizer Europe MA EEIG
- NorwaySomavertPfizer Europe MA EEIG (1)
- PolandSomavertPfizer Europe MA EEIG
- SwedenSOMAVERT 10 mg Pulver och vätska till injektionsvätska, lösningPfizer Europe MA EEIG
- FinlandSomavertPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Somavert
- Liechtenstein · Somavert
- Norway · Somavert
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6a45fbd8-338e-4414-b8d2-fb300e19e0e7 GET /v1/drugs/6a45fbd8-338e-4414-b8d2-fb300e19e0e7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02272210",
"form": "KIT",
"class": "Human",
"routes": [
"SUBCUTANEOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "H01AX01",
"schedule": [
"Schedule D",
"Prescription"
],
"drug_code": "75775",
"strengths": [
"20 MG"
],
"ahfs_class": null,
"substances": [
"PEGVISOMANT"
],
"product_categorization": null
}See everything about pegvisomant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.